Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

U.S. Study of Fibrocaps in Surgical Hemostasis

NCT01256164
Conditions
Postoperative Hemorrhage
Interventions
Fibrocaps (fibrin sealant), Gelfoam
Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Obstructive Sleep Disorder, Obstructive Sleep Apnea, Tonsillar Hypertrophy
Interventions
Micropolysaccharide Hemospheres (Arista), Electrocautery (Monopolar suction cautery)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Not yet recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Allergic Asthma
Interventions
Albuterol sulfate
Drug
Lead sponsor
Respirics Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Terminated No phase listed Observational

EPR Tumor Oximetry With CE India Ink

NCT03321903
Conditions
Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
Interventions
Carlo Erba Ink Injection, EPR Oximetry Measurement
Device · Other
Lead sponsor
Philip Schaner
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Vaginitis, Dyspareunia, Breast Neoplasms
Interventions
Testosterone propionate
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Burlington, Vermont
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Conditions
Open Fracture
Interventions
Vancomycin (VAN) treatment, Standard Open Fracture Care
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Oral Squamous Cell Carcinoma
Interventions
PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable)
Drug
Lead sponsor
Privo Technologies
Industry
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Duarte, California • Miami, Florida • Chicago, Illinois + 1 more
Conditions
Acne Rosacea
Interventions
Topical Powder, Placebo Topical Powder
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer

NCT02142543
Conditions
Minor Recurrent Aphthous Stomatitis Lesions
Interventions
2-DeNT powder, Placebo Comparator
Drug
Lead sponsor
Texas A&M University
Other
Eligibility
12 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Post Operative Surgical Site Infection
Interventions
Treatment group, Control group
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Redwood City, California + 35 more
Conditions
Open Fracture
Interventions
Vancomycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Antonio, Texas